biopharmaceutical company, reported preclinical data on the company's first product, Thrombosphere synthetic platelets, at the Congress of the International Society on Thrombosis and Haemostasis in Jerusalem this week.
Thrombosphere synthetic platelets are designed to provide a safe, cost-effective alternative in a treatment area where no competing product is currently available.
In vivo studies in severely thrombocytopenic rabbits indicate that Thrombospheres appear to be a safe hemostatic agent in that doses larger than needed for hemostatic efficacy in thrombocytopenic animals showed no thrombogenicity.
Several different forms of platelet substitute are now under development: infusible platelet membranes (IPM), thrombospheres, and lyophilized human platelets.
Thrombospheres (Hemosphere, Irvine, Calif) are not platelets; they are composed of cross-linked human albumin with human fibrinogen bound to the surface.